Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Annovis Bio, Inc. (ANVS : NYSE)

• Company Description    Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $2.23 Daily Weekly Monthly 20 Day Moving Average: 1,139,993 shares Shares Outstanding: 34.65 (millions) Market Capitalization: $77.26 (millions) Beta: 1.26 52 Week High: $5.50 52 Week Low: $1.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 23.20% 17.19% 12 Week -19.49% -25.58% Year To Date -35.55% -42.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 101 Lindenwood Drive Suite 225 - Malvern,PA 19355 USA ph: 484-875-3192 fax: - ir@annovisbio.com http://www.annovisbio.com

• General Corporate Information    Officers Maria Maccecchini - President and Chief Executive Officer Michael Hoffman - Chairman of the Board and Director Mark Guerin - Chief Financial Officer Claudine Bruck - Director Reid McCarthy - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03615A108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 34.65 Most Recent Split Date: (:1) Beta: 1.26 Market Capitalization: $77.26 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 24.72 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -96.88% vs. Previous Quarter: -61.54% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -318.08 12/31/25 - -159.43 09/30/25 - -153.50 ROA 03/31/26 - -215.47 12/31/25 - -133.49 09/30/25 - -125.51 Current Ratio 03/31/26 - 1.27 12/31/25 - 5.80 09/30/25 - 4.60 Quick Ratio 03/31/26 - - 12/31/25 - 5.80 09/30/25 - 4.60 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.09 12/31/25 - 0.64 09/30/25 - 0.54 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©